Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of anti-angiogenic drugs in advanced renal cancer (China)
ChiCTR2100044075Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in renal cell carcinoma (RCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Started May 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2100044075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044075.